Idera Pharmaceuticals traded at $0.44 this Friday July 1st, decreasing $0.02 or 4.58 percent since the previous trading session. Looking back, over the last four weeks, Idera Pharmaceuticals lost 39.99 percent. Over the last 12 months, its price fell by 62.56 percent. Looking ahead, we forecast Idera Pharmaceuticals to be priced at 0.32 by the end of this quarter and at 0.30 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
0.44
Daily Change
-4.58%
Yearly
-62.56%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Abbott 110.22 1.57 1.45% -6.62%
Agenus 1.96 0.02 1.03% -64.49%
Alnylam Pharmaceuticals 148.25 2.40 1.65% -13.52%
Amgen 245.55 2.25 0.92% -1.27%
Biogen 210.63 6.69 3.28% -39.60%
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
CytrRx Corporation 0.10 0.01 7.19% -90.00%
Dynavax Technologies 12.96 0.37 2.94% 30.91%
Gilead Sciences 62.36 0.55 0.89% -10.01%
GlaxoSmithKline 1,785.60 20.00 1.13% 24.19%
Idera Pharmaceuticals 0.44 -0.02 -4.58% -62.56%
Eli Lilly 324.71 0.48 0.15% 38.79%
Merck & Co 92.42 1.25 1.37% 17.58%
Mirati Therapeutics 71.18 4.05 6.03% -57.53%
Nektar Therapeutics 3.75 -0.05 -1.32% -78.08%
Pfizer 52.31 -0.12 -0.23% 31.66%
Ultragenyx Pharmaceutical 62.65 2.99 5.01% -33.50%
Roche Holding 320.40 1.85 0.58% -8.34%
Seattle Genetics 180.11 3.17 1.79% 14.52%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
X T L Biopharmaceuticals 1.49 -0.03 -1.91% -62.18%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Idera Pharmaceuticals
Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists and antagonists to act by modulating the activity of targeted TLRs. Its TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The Company is developing tilsotolimod, via intratumoral injection in combination with inhibitors and costimulation therapies for the treatment of various solid tumors, including anti-programmed-death-receptor-1 (anti-PD1) refractory metastatic melanoma, microsatellite stable (MSS) colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (HNSCC). It refers tilsotolimod development program as the ILLUMINATE development program.